Alphyn is using its AB-101 drug platform to develop safer, more effective therapeutics, initially for the $118 Billion Atopic Dermatitis (AD) market. After only 3½ years, Alphyn's first drug candidate, topical AB-101a, completed two Phase 2a clinical trials in AD with market-leading results, providing a faster path to regulatory approval and a huge commercial opportunity, with clinical results pointing to it being the "drug of choice" for this vast 800 million patient population.